Added to YB: 2026-03-17
Pitch date: 2026-03-13
RYTM [neutral]
Rhythm Pharmaceuticals, Inc.
+2.21%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Market Cap
$6.0B
Pitch Price
$88.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-30.53
P/E
-28.12
EV/Sales
30.68
Sector
Biotechnology
Category
growth
DD: Rhythm Pharmaceuticals ($RYTM)
RYTM (overview): MC4R agonist setmelanotide for hypothalamic obesity showed 16.4% BMI reduction vs 2.4% placebo increase (p<0.0001) in 142-patient TRANSCEND trial. March 20, 2026 PDUFA key catalyst. Q1 2026 EMANATE data for heterozygous variants critical. $388.9M cash, $16.8M/mo burn = runway to H2 2027. FY25 rev $194.8M (+50% YoY), but net loss $201.9M. rNPV $72/share assumes 95% approval odds for hypothalamic obesity ($42/share), 40% for EMANATE ($22/share). Risks: small trial size, psychiatric AEs, heterozygous non-responders, GLP-1 competition, high SG&A. Neutral.
Read full article (6 min)